Obesity and Diabetes
Quigley Begins Human Trial to Investigate Effects of Broad Spectrum Anti-Inflammatory Compound on Metabolic Syndrome Patients
Published in Obesity and Diabetes Week, August 13th, 2007
Quigley Pharma, www.QuigleyPharma.com, a wholly owned subsidiary of The Quigley Corporation (NASDAQ:QGLY) announced that based on positive preclinical animal data and Institutional Review Board (IRB) approval it has initiated a human clinical safety trial designed to evaluate the effects of QR-449 on subjects with Metabolic Syndrome. People suffering from Metabolic Syndrome are vulnerable to the most dangerous heart attack risk factors; diabetes, abdominal obesity, high cholesterol and high blood pressure.
The primary objectives for the study are; the determination of safety and to measure the corrective capacity of the compound on the imbalance of important...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Obesity and Diabetes
Obese patients get patchy weight-loss support from their local health surgery - Obesity and Diabetes
Reducing inflammation plays key role in type 1 diabetes therapy - Bariatrics
HealthGrades Study: Bariatric Surgery Patients Have Fewer Complications at High-Volume Hospitals - Epidemic
RevolutionHealth.com Charts Obesity Epidemic in U.S.: 1990-2006 - Obesity and Diabetes
Genaera Corporation Presents New Preclinical Data for Obesity Compound Trodusquemine (MSI-1436) at CBI Conference - Obesity and Diabetes
OREXIGEN Therapeutics to Present CONTRAVE Clinical Summary at CBI's 3rd Annual Obesity Drug Development Summit - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
